logo

Follow/Share
  • About
  • Careers
  • Events
  • Contact
  • Diversity
  • Alumni
  • English
    • 普通話

Ian Scott

Member

New York
277 Park Avenue
New York, New York 10172
P
(212) 908-1205
TF
(800) 437-7040
F
(646) 588-1424
  • People
    • A
    • B
    • C
    • D
    • E
    • F
    • G
    • H
    • I
    • J
    • K
    • L
    • M
    • N
    • O
    • P
    • Q
    • R
    • S
    • T
    • U
    • V
    • W
    • X
    • Y
    • Z
    • |
    • View all people



  • Industries
    • Energy & Utilities
    • Food & Beverage
    • Gaming
    • Health Care & Life Sciences
    • Insurance
    • Media, Entertainment & Sports
    • Real Estate & Construction
    • Technology
    • Transportation & Logistics
    • Venture Capital
  • Practice Areas
      • Antitrust & Trade Regulation
      • Bankruptcy, Insolvency & Restructuring
      • China Practice
      • Corporate
      • Emerging Business & Venture Capital
      • Energy, Environmental & Public Utilities
      • Health Care
      • International
      • Mergers & Acquisitions
      • Private Client Services
      • Public & Project Finance
      • Securities
      • Tax
      • Transportation & Logistics
      Business/Corporate
      • Antitrust & Trade Regulation
      • Aviation
      • Consumer Protection & Privacy
      • Cozen O'Connor Public Strategies - Government Relations
      • Energy, Environmental & Public Utilities
      • Health Care
      • Privacy & Data Security
      • Transportation & Logistics
      Government & Regulatory
      • Bad Faith
      • Cyber/Technology
      • Insurance Corporate & Regulatory
      • Insurance Coverage & Claims Litigation
      • Professional Liability Insurance Coverage
      • Reinsurance
      • Subrogation & Recovery
      Insurance
      • Biologics/Biosimilars
      • Domains
      • e-commerce
      • Entertainment Law
      • Franchising
      • Hatch-Waxman Litigation
      • Intellectual Property Litigation
      • Licensing & Transfer
      • Patents
      • Right of Privacy & Right of Publicity
      • Trade Secrets & Unfair Competition
      • Trademark & Copyright
      Intellectual Property
      • Employee Benefits & Executive Compensation
      • Employment Litigation
      • Immigration
      • Labor Relations & Disputes
      • Trade Secrets & Unfair Competition
      Labor & Employment
      • Antitrust Litigation & Investigations
      • Appellate
      • Aviation
      • Bankruptcy, Insolvency & Restructuring
      • Complex Litigation
      • Construction
      • Cyber/Technology
      • Electronic Discovery
      • Energy, Environmental & Public Utilities
      • Family Law
      • Franchise Disputes
      • Health Care
      • Insurance Coverage & Claims Litigation
      • Intellectual Property Litigation
      • Internal Investigations & Criminal Defense
      • Products Liability
      • Professional Liability
      • Real Estate Litigation
      • Securities Litigation & Enforcement
      • Self-insured Recovery
      • Transportation & Logistics Litigation
      Litigation
      • Brownfields Development
      • Distressed Real Estate
      • Eminent Domain
      • Office/Retail/Industrial Leasing & Development
      • Real Estate Finance
      • Real Estate Litigation
      • Zoning, Land Use & Development
      Real Estate
      • Subrogation & Recovery
    • Experience
      • Client Stories
      • Experience
    • Offices
      • Atlanta
      • New York
      • Charlotte
      • Philadelphia
      • Cherry Hill
      • San Diego
      • Chicago
      • Seattle
      • Dallas
      • Toronto
      • Denver
      • Washington, D.C.
      • Harrisburg
      • West Conshohocken
      • Houston
      • West Palm Beach
      • London
      • Wilkes-Barre
      • Los Angeles
      • Wilmington
      • Miami
    • News & Resources
      • Blogs
      • News & Resources
      • Media Resources
      • Publications
    • OVERVIEW
    • EXPERIENCE
    • NEWS

    Ian Scott

    Ian Scott joined the firm in 2012 as a member of the Intellectual Property Practice Group in the firm's New York office. Ian's practice is concentrated on patent litigation, with an emphasis in pharmaceutical patent litigation under the Hatch-Waxman Act. He has extensive experience in the preparation of legal opinions in connection with planning for litigation, including opinions regarding patentability, invalidity, freedom-to-operate and priority of invention of U.S. patents and publications.

    Ian also provides counseling for clients in connection with the protection of their intellectual property rights and avoidance of third-party rights. He is experienced in all areas of the preparation, prosecution and exploitation of patent applications, including licensing of intellectual property rights and due diligence analyses. He counsels clients in a broad array of technical fields, including pharmaceuticals and pharmaceutical formulations, chemistry and chemical processes, industrial gases and related applications, medical devices, small molecules, polymers, polymer blends and dispersions, UV absorbers, cosmetics and golf equipment.

    Prior to practicing law, Ian worked for more than nine years in the chemical industry, becoming a senior chemist at E.M. Industries, an affiliate of Merck KGaA, Darmstadt. He carried out and oversaw applied research and development in the areas of specialty pigments and sunscreen active materials, and the formulation of related personal care products. He also carried out research and development in the area of solution phase deposition processes. Ian also participated in the commercialization and marketing of specialty pigment, sunscreen active and chemical raw material products.

    He earned his master's degree in chemistry from St. John's University and his bachelor's degree in chemistry, with honors, from University College Swansea, University of Wales. He graduated from Pace University School of Law in 1996.

    Represented Apotex Inc., in a patent infringement action regarding Apotex’s ANDA to make a generic version of LYSTEDA (tranexamic acid). Matter pending.


    Represented Apotex Inc., in a patent infringement action regarding Apotex’s ANDA to make a generic version of PRISTIQ® (desvenlafaxine). Matter pending.


    Represented Sandoz Inc., in a patent infringement action regarding Sandoz's ANDA to make a generic version of Shire’s ADHD product INTUNIV® (guanfacine hydrochloride). Matter pending.


    Represented our client, Sandoz Inc., in patent infringement action regarding Sandoz’s ANDA to make a generic version of Helsinn’s anti-nausea product ALOXI® (palonosetron hydrochloride injection). Matter pending.


    Represented Sandoz Inc., in a patent infringement action regarding Sandoz’s ANDA to make a generic version of Roche’s VALCYTE® (valganciclovir hydrochloride). Matter pending.


    Represented our client in a patent infringement action regarding Apotex’s ANDA to make a generic version of AVODART® (dutasteride). Matter pending.


    Represented Apotex Inc., in a patent infringement action regarding Apotex’s ANDA to make a generic version of ACULAR LS® (0.4% ketorolac tromethamine). Matter pending.


    Represented our client, Sandoz Inc., in a patent infringement action regarding Sandoz’s ANDA to make a generic version of Abbott’s cholesterol product NIASPAN® (niacin). Matter pending.


    Represented our client, Sandoz Inc., in a patent infringement action regarding Sandoz's ANDA to make a generic version of Abbott’s ZEMPLAR® (paricalcitol).


    Represented Apotex Inc., in a patent infringement action regarding Apotex's ANDA to make a generic version of Sanofi-Aventis' anticancer product TAXOTERE®, the active ingredient of which is docetaxel. Following a two-week trial, obtained an order for Apotex striking down the patents-in-issue as invalid as obvious and unenforceable due to Sanofi-Aventis' inequitable conduct in procuring the patents. Successfully argued on appeal with the Federal Circuit affirming trial court decision (April 2012). Of import is that inequitable conduct defense remains viable in ANDA litigations because of this ruling.


    Handled a patent infringement action regarding Apotex's ANDA to make a generic version of Pfizer's migraine product Relpax®, the active ingredient of which is eletriptan hydrobromide.


    Represented Sandoz Inc. in a patent infringement action regarding Eon/Sandoz's abbreviated new drug application (ANDA) to make a generic version of Pfizer’s anti-seizure product Neurontin®, the active ingredient of which is gabapentin.


    Represented our client, Sandoz Inc., in a patent infringement action regarding Sandoz's ANDA to make a generic version of Allergan's glaucoma drops COMBIGAN® (brimonidine tartrate/timolol maleate.)


    Represented Apotex Inc., in a patent infringement action regarding Apotex's ANDA to make a generic version of Wyeth's anti-depressant product EFFEXOR XR® (venlafaxine hydrochloride). Settled on favorable terms during trial.


    Lead counsel for Sandoz Inc., in a patent infringement action regarding Sandoz's ANDA to make a generic version of Endo's pain product OPANA® ER (oxymorphone hydrochloride).


    Handled a patent infringement action regarding Sandoz's ANDA to make a generic version of Pfizer’s antimuscarinic tablet Detrol and Detrol LA®, the active ingredient of which is tolterodine tartrate.


    Represented Sandoz Inc., in a patent infringement action regarding Sandoz's ANDA to make a generic version of Merck's anti-nausea product EMEND® (aprepitant).


    Represented Apotex Inc., in a patent infringement action regarding Apotex's ANDA to make a generic version of Procter's osteoporosis product ACTONEL® (risedronate).


    Represented our client, Sandoz Inc., in a patent infringement action regarding Sandoz's ANDA to make a generic version of Medicis' acne product SOLODYN® (minocycline hydrochloride).


    Handled a patent infringement action regarding Schwarz Pharma’s ANDA to make a generic version of Braintree Labs’ constipation product Miralax®, the active ingredient of which is polyethylene glycol. During discovery, Braintree dismissed its infringement complaint, waiving the remaining portion of the 30 month stay on FDA approval of Schwarz Pharma’s product.


    Additional Practices

    News


    Cozen O’Connor Continues Growth of IP Litigation Practice with Seven Partners, Two Associates from Duane Morris

    April 16, 2012

    Cozen O’Connor Continues Growth of IP Litigation Practice with Seven Partners, Two Associates from Duane Morris

    MORE

    Publications

    There are no PUBLICATIONS at this time. Please try back at a later time.

    Practice Areas

    Intellectual Property

    Biologics/Biosimilars

    Hatch-Waxman Litigation

    Intellectual Property Litigation

    Education

    • Pace University School of Law, J.D., 1996
    • St. John's University, M.S., 1994
    • University College Swansea, University of Wales, B.Sc., 1988

    Bar Admissions

    • New Jersey
    • New York
    • United States Patent and Trademark Office

    Court Admissions

    • U.S. District Court -- New Jersey
    • U.S. District Court -- Eastern District of New York
    • U.S. District Court -- Southern District of New York
    • U.S. Court of Appeals for the Federal Circuit
    • Sitemap
    • Advanced Search
    • Disclaimer
    • Privacy Policy
    • Attorney Advertising